Patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes had a 44% reduction in liver fat after receiving Inventiva Pharma SA’s PPAR agonist, lanifibranor, in a phase II trial, findings that caused the Daix, France-based company’s stock to soar.